- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Schizophrenia
- Meeting Date: March 2026
- Public Summary Document (PSD) March 2026 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2026 PBAC Meeting - (DOCX)
Risperidone – March 2026
Subcutaneous injection (modified release) 50 mg in 0.14 mL pre-filled syringe, Subcutaneous injection (modified release) 75 mg in 0.21 mL pre-filled syringe, Subcutaneous injection (modified release) 100 mg in 0.28 mL pre-filled syringe, Subcutaneous injection (modified release) 125 mg in 0.35 mL pre-filled syringe
Last updated
11 March 2026